Search

In today’s medical world, the patient’s data with symptoms and diseases are expanding rapidly, so that analysis of all factors with updated knowledge about symptoms and corresponding new treatment is merely not possible by medical experts. Hence, the essential for an intelligent system to reflect the different issues and recognize an appropriate model between the different parameters is evident. In recent decades, rough set theory (RST) has been broadly applied in various fields such as medicine, business, education, engineering and multimedia. In this study, a hybrid intelligent system that combines rough set (RST) and bijective soft set theory (BISO) to build a robust classifier model is proposed. The aim of the hybrid system is to exploit the advantages of the constituent components while eliminating their limitations. The resulting approach is thus able to handle data inconsistency in datasets through rough sets, while obtaining high classification accuracy based on prediction using bijective soft sets. Toward estimating the performance of the hybrid rough-bijective soft set (RBISO)-based classification approach, six benchmark medical datasets (Wisconsin breast cancer, liver disorder, hepatitis, Pima Indian diabetes, echocardiogram data and thyroid gland) from the UCI repository of machine learning databases are utilized. Experimental results, based on evaluation in terms of sensitivity, specificity and accuracy, are compared with other well-known classification methods, and the proposed algorithm provides an effective method for medical data classification. [ABSTRACT FROM AUTHOR]

Background: Mutations in the K-Ras gene are among the most frequent genetic alterations in various cancers, and inhibiting RAS signaling has shown promising results in treating solid tumors. However, finding effective drugs that can bind to the RAS protein remains challenging. This drove us to explore new compounds that could inhibit tumor growth, particularly in cancers that harbor K-Ras mutations., Methods: Our study used bioinformatic techniques such as E-pharmacophore virtual screening, molecular simulation, principal component analysis (PCA), extra precision (XP) docking, and ADMET analyses to identify potential inhibitors for K-Ras mutants G12C and G12D., Results: In our study, we discovered that inhibitors such as afatinib, osimertinib, and hydroxychloroquine strongly inhibit the G12C mutant. Similarly, hydroxyzine, zuclopenthixol, fluphenazine, and doxapram were potent inhibitors for the G12D mutant. Notably, all six of these molecules exhibit a high binding affinity for the H95 cryptic groove present in the mutant structure. These molecules exhibited a unique affinity mechanism at the molecular level, which was further enhanced by hydrophobic interactions. Molecular simulations and PCA revealed the formation of stable complexes within switch regions I and II. This was particularly evident in three complexes: G12C-osimertinib, G12D-fluphenazine, and G12D-zuclopenthixol. Despite the dynamic nature of switches I and II in K-Ras, the interaction of inhibitors remained stable. According to QikProp results, the properties and descriptors of the selected molecules fell within an acceptable range compared to sotorasib., Conclusions: We have successfully identified potential inhibitors of the K-Ras protein, laying the groundwork for the development of targeted therapies for cancers driven by K-Ras mutations., Competing Interests: The authors declare no conflict of interest. As C. George Priya Doss was one of guest editors of the journal, we declare that he had no involvement in the peer-review of this article and has no access to information regarding its peer-review. Full responsibility for the editorial process for this article was delegated to Milena Georgieva., (© 2023 The Author(s). Published by IMR Press.)